Media OutReach
Bupa Hong Kong Launches “Bupa Care Bridge”, an Affordable Health Insurance Solution Designed for Cross‑border Living
New medical plan combines cashless inpatient protection across Hong Kong and Mainland China with embedded outpatient and preventive care in Hong Kong
HONG KONG SAR – Media OutReach Newswire – 18 May 2026 – Bupa Hong Kong today announced the launch of Bupa Care Bridge Health Insurance Scheme, a new medical insurance solution designed to support Hong Kong residents whose lives increasingly span Hong Kong and Mainland China, and who are seeking affordable, practical health protection that covers both major medical events and everyday healthcare needs.
Cross‑border healthcare has become a growing reality for many Hong Kong people. In 2024 alone, Hong Kong residents made approximately 700,000 medical visits in Shenzhen, reflecting rising familiarity with receiving medical services across the border for efficiency, convenience and follow‑up care. At the same time, most continue to rely on Hong Kong for routine outpatient consultations, ongoing care and long‑term health management.
Bupa Care Bridge is designed around this reality. The scheme provides inpatient coverage across Hong Kong and Mainland China, while anchoring outpatient and preventive care in Hong Kong, where everyday healthcare is most frequently accessed. Designed with affordability in mind, the scheme offers two plan levels and flexible deductible options that allow customers to balance premium levels with the degree of protection they need, making the plan relevant to young adults, cross‑border professionals and retirees, including those managing healthcare costs over the long term.
Rather than positioning outpatient care as an optional add-on, Bupa Care Bridge embeds outpatient services within the medical plan itself, helping customers manage everyday healthcare costs more predictably while maintaining comprehensive inpatient protection.
Key features of Bupa Care Bridge include:
- Cashless inpatient care at designated hospitals, subject to pre-authorisation, with entitlement to standard private room accommodation in Mainland China and semi-private room accommodation in Hong Kong, providing greater certainty and comfort during hospital stays.
- Inpatient coverage across Mainland China or Greater China (Hong Kong, Macau, Mainland China and Taiwan), based on plan level, with worldwide coverage for emergency treatment to support major medical needs wherever they arise.
- Embedded outpatient care in Hong Kong, supporting everyday healthcare needs and follow-up care outside hospital settings (only applicable to Bupa Care Bridge Health Insurance Scheme Plus Plan). Covered services include general practitioner and specialist consultations, traditional Chinese medicine, physiotherapy, and X-ray and laboratory tests.
- Clear, predictable co‑payments for outpatient services, helping customers manage routine healthcare costs — with GP consultations from HK$40 per visit, specialist consultations from HK$60 per visit, and defined co‑payments for other outpatient services.
- Simplified underwriting with a streamlined health questionnaire, reducing friction at enrolment.
- Guaranteed lifetime renewal, providing long‑term certainty as healthcare needs evolve.
- Care coordination support for cross-border hospital treatment, including assistance with arranging transportation at discharge from hospital to home in Hong Kong and Shenzhen.
The scheme also supports preventive care, offering access to health check‑ups to encourage early detection and ongoing health monitoring, helping customers take a more proactive approach to managing their health rather than reacting only when serious illness occurs.
By combining affordable everyday outpatient care in Hong Kong with cashless inpatient protection across borders, Bupa Care Bridge supports both short‑term healthcare needs and longer‑term health planning in a more connected region.
Bupa Care Bridge Health Insurance Scheme is now available for enrolment. For more information, please visit www.bupa.com.hk/en/care-bridge.
Hashtag: #保柏香港 #BupaHongKong #跨境醫療 #CrossBorderHealthcare #GreaterChina
The issuer is solely responsible for the content of this announcement.
Bupa – An international health insurance specialist
Established in 1947, Bupa’s purpose is helping people live longer, healthier, happier lives and making a better world. We are an international healthcare company serving over 68 million customers worldwide. With no shareholders, we reinvest profits into providing more and better healthcare for the benefit of current and future customers. Bupa has businesses around the world, principally in Australia, the UK, Spain, Poland, Chile, Hong Kong SAR, India, Türkiye, Brazil, Mexico and New Zealand. We also have associate businesses in Saudi Arabia.
Bupa has been a health insurance specialist in Hong Kong since 1976, offering one-stop solutions across domestic and international health insurance, and healthcare services. Our comprehensive medical insurance schemes are tailored to meet individual needs, and we provide health solutions for companies of all sizes. We also have a team of registered nurses, health management professionals, and doctors who provide various expert healthcare support.
Our healthcare provision arm, Quality HealthCare Medical Services (QHMS), became part of Bupa in October 2013. QHMS offers Western Medicine, Traditional Chinese Medicine, Diagnostics & Imaging, Physiotherapy, Mental Health and Wellness services via a network of over 1,650 provider service points in Hong Kong.
For more information, visit 
www.bupa.com.hk/en/.
Through DaaS, enterprise customers can access drone equipment, trained personnel, mission execution, data collection and project deliverables without purchasing and maintaining a complete in-house drone system. The model extends ZenaTech’s business beyond equipment sales and enables the company to generate recurring service revenue from customers’ operational requirements.
ZenaTech reported revenue of CAD 8.4 million for the first quarter of 2026, an increase of 640% from CAD 1.13 million in the same period of 2025. DaaS contributed approximately CAD 7.8 million, accounting for around 93% of quarterly revenue.
In 2025, the company generated annual revenue of CAD 12.9 million, up 558% from approximately CAD 2 million in 2024. DaaS contributed approximately CAD 10.1 million during its first full year of operations, representing around 78% of total annual revenue.
Acquisitions Support Service Network Expansion
ZenaTech has expanded its DaaS operations through a combination of internal technology development and acquisitions. The acquired businesses bring existing customers, professional teams and local operating capabilities, while ZenaTech gradually introduces drones, automated data collection and AI-supported analytics into selected workflows.
In 2025, the company completed 20 acquisitions, including 19 businesses providing engineering data, facility inspection and related professional services, as well as one enterprise software company.
By June 2026, ZenaTech had completed its 24th DaaS-related acquisition and expanded its services into property cleaning, facility inspection and maintenance.
Through its ZenaDrone subsidiary, ZenaTech has also developed drone products for indoor and outdoor operations. The IQ Quad supports site data collection, engineering imagery and 3D modelling, while the IQ Nano uses barcode and RFID scanning to support inventory records, shelf inspections and indoor data collection.
The company’s reported revenue growth, acquisition activity and DaaS contribution provide investors following the AI and drone sectors with measurable indicators of how its technologies are being integrated into commercial operations and converted into service revenue.
Hashtag: #ZenaTech
The issuer is solely responsible for the content of this announcement.
About ZenaTech
ZenaTech (Nasdaq: ZENA) is a technology company specialising in AI-powered drones, Drone-as-a-Service (DaaS), enterprise SaaS solutions and related technologies. Through its ZenaDrone subsidiary, the company develops drone products and software for commercial applications including engineering data collection, agriculture, warehouse management, facility inspection and property maintenance. ZenaTech combines its technology capabilities with a growing professional service network to support the adoption of drone-based solutions across a range of operational environments.
Media OutReach
A Defining Milestone for Gene Solutions: SPOT-MAS Multi-Cancer Screening Test Receives U.S. FDA Breakthrough Device Designation
The proposed indications for use describe SPOT-MAS 10 as a qualitative in vitro diagnostic test performed on plasma derived from a single direct-draw venous whole blood specimen. The test analyzes circulating cell-free DNA methylation and fragmentomic signatures using a machine-learning-based algorithm to detect a cancer-associated signal. It is intended for use as an adjunctive screening test in asymptomatic adults aged 40 years and older to assist in detecting cancers within the scope of the assay. These include five common cancers — breast, lung, liver, colorectal and gastric cancers — and five aggressive, less common cancers that currently lack standard screening methods — ovarian, pancreatic, esophageal, endometrial and head & neck cancers.
SPOT-MAS has been developed through years of rigorous scientific research and clinical development. In March 2025, SPOT-MAS became the first multi-cancer screening blood test in Asia to complete a large prospective cohort validation, with the K-DETEK study evaluating more than 9,000 asymptomatic participants and demonstrating strong performance, including high specificity and the ability to identify cancer-associated signals across multiple cancer types.
Since then, SPOT-MAS has been used in more than 100,000 individuals in real-world practice, with consistent performance observed beyond controlled study settings. Real-world data were presented at ESMO Asia 2025 and were featured at ASCO Breakthrough 2026 in Singapore.
The platform is built on a multi-omic approach— integrating genetics, epigenetics, and fragmentomics — together with AI-driven analysis, large-scale prospective validation, growing real-world evidence and focus on cancer types with high clinical relevance in the regions where the test is deployed.
For the United States, Breakthrough Device Designation provides Gene Solutions with a prioritized channel of engagement with the FDA as the company advances its U.S. development and validation plans.
Looking ahead, Gene Solutions will continue to collaborate with academic, clinical, laboratory, commercial and strategic partners to support responsible adoption of SPOT-MAS in accordance with local regulations, clinical guidelines and best practices.
Important Regulatory Notice: SPOT-MAS 10 has received U.S. FDA Breakthrough Device Designation. Breakthrough Device Designation is not FDA approval, clearance or marketing authorization. The device remains subject to applicable FDA regulatory review requirements, and the designation does not guarantee future FDA approval, clearance or authorization.
For more information, visit https://spotmas.com.hk
Contact:
hk***@***********ns.com
Source: Gene Solutions Hong Kong Limited.
SPOTMAS_062026_04
Hashtag: #SPOTMAS
https://spotmas.com.hk/The issuer is solely responsible for the content of this announcement.
Media OutReach
St Francis Methodist School International Shares 2023–2024 WACE Outcomes and Student Journeys
Overview of the WACE Curriculum at SFMS
SFMS International is among a small number of institutions in Singapore offering the WACE curriculum and has delivered this programme for over 23 years. The WACE is a recognised senior secondary qualification awarded by the School Curriculum and Standards Authority (SCSA) on behalf of the Ministry of Education, Western Australia. It prepares students for university admission both locally and internationally.
SFMS is also currently the only school in Singapore offering a Senior High Preparatory Pathway (WACE) for students in Years 9–10. This introduces students to the structure and expectations of the curriculum earlier, building familiarity with subject content and assessment formats before progressing to the senior years. Additionally, subject selection in Years 11A and 12A is structured to meet university entry requirements and reflect students’ academic interests.
Academic Outcomes and University Placements
In 2023, 8 out of 12 WACE graduates from SFMS International achieved ATAR scores above 90, meeting the eligibility criteria for universities such as the National University of Singapore (NUS) and Nanyang Technological University (NTU). The cohort’s top scorer, Wang Dawei, recorded an ATAR of 96.15 and enrolled at NTU to study Business and International Trading. In addition to local placements, graduates were admitted to international universities such as the University of Melbourne and Fudan University in China.
In 2024, 2 out of 8 graduates also attained ATAR scores above 90. The highest scorer, Youn Chae-Won, achieved an ATAR of 95.3. Her university placement is currently pending.
Student Journeys and Holistic Development
Students in the WACE programme at SFMS International engage in both academic and co-curricular activities as part of their overall learning experience. Recent graduates have taken part in service learning, subject specialisation, and personal reflection throughout their time in the pre-university programme.
Youn Chae-Won, the 2024 valedictorian, joined SFMS International from Korea in 2021. Over time, she adjusted to a new academic environment and explored subjects such as accounting, which influenced her interest in finance-related pathways. She also took part in various aspects of school life, including a service learning trip to Bintan in 2023, where students supported local sanitation efforts. Her involvement in both academic and co-curricular settings marked a broad engagement with school life during her time at SFMS.
Andrew Zhuang, who enrolled in SFMS International in 2019, pursued subjects such as Business Management, Accounting, and English as an Additional Language (EALD). Beyond academics, he was involved in community fundraising and joined the same Bintan service trip. He also attended weekly chapel sessions and received support from peers and teachers during a period of health-related absence.
These outcomes reflect the ongoing role of the WACE programme at SFMS International in supporting students through both academic pathways and broader educational experiences. Under the leadership of Principal Mr Lee Hak Boon, the school continues to emphasise academic planning, subject selection, and student wellbeing as part of its overall approach to pre-university education.
Hashtag: #StFrancisMethodistSchoolInternational
https://www.sfms.edu.sg/
https://www.facebook.com/sfms.singapore
https://www.instagram.com/sfms_sg/
https://www.youtube.com/channel/UC_bb9hcNhAk7WgYBE_FI61A/featured
The issuer is solely responsible for the content of this announcement.
About St Francis Methodist School International
Established in 1960, St Francis Methodist School International (SFMS) is an educational institution in Singapore that offers primary, secondary, and pre-university programmes. The school provides several academic pathways, including the International Baccalaureate (IB), Cambridge IGCSE, and the Western Australian Certificate of Education (WACE), preparing students for further studies in local and overseas institutions.
